Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Consolidated Net Income: 2010-2024

Historic Consolidated Net Income for Northwest Biotherapeutics (NWBO) over the last 15 years, with Dec 2024 value amounting to -$74.3 million.

  • Northwest Biotherapeutics' Consolidated Net Income fell 0.36% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$73.4 million, marking a year-over-year decrease of 5.42%. This contributed to the annual value of -$74.3 million for FY2024, which is 22.27% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its Consolidated Net Income stood at -$74.3 million for FY2024, which was down 22.27% from -$60.7 million recorded in FY2023.
  • Northwest Biotherapeutics' Consolidated Net Income's 5-year high stood at -$57.7 million during FY2021, with a 5-year trough of -$95.1 million in FY2020.
  • For the 3-year period, Northwest Biotherapeutics' Consolidated Net Income averaged around -$69.4 million, with its median value being -$73.2 million (2022).
  • In the last 5 years, Northwest Biotherapeutics' Consolidated Net Income plummeted by 207.39% in 2020 and then surged by 39.34% in 2021.
  • Northwest Biotherapeutics' Consolidated Net Income (Yearly) stood at -$95.1 million in 2020, then soared by 39.34% to -$57.7 million in 2021, then declined by 26.92% to -$73.2 million in 2022, then climbed by 17.07% to -$60.7 million in 2023, then declined by 22.27% to -$74.3 million in 2024.